ArticleBMC genomics2014
Insights into naturally minimised Streptomyces albus J1074 genome.
Article in BMC genomics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 179 citations in OpenAlex.
- Review
- Targeted identification of new phaterpenes and elucidation of the relevant biosynthetic pathway inSynthetic and systems biotechnology · 2026Article
- Unconventional Biocatalytic Strategies Orchestrate the Synthesis of the Nucleoside Analog Sinefungin.Journal of the American Chemical Society · 2026Article
- Unveiling Aziridine-Containing Natural Products by Genomic and Spectroscopic Approaches.Angewandte Chemie (International ed. in English) · 2026Article
- Heterologous production of a plant biostimulant in Streptomyces albidoflavus.Applied microbiology and biotechnology · 2026Article
- Heterologous production of epothilones inSynthetic and systems biotechnology · 2026Article
- Unraveling rare codon bias in Actinomycetota: lineage-specific and 5' terminal enrichment across 1936 genomes.BMC genomics · 2026Article
- Genome minimization of a Burkholderia bacterial host.Metabolic engineering · 2026Article
- Single copy optogenetic system for Streptomyces.Scientific reports · 2025Article
- Engineering Polyketide Stereocenters with Ketoreductase Domain Exchanges.Journal of the American Chemical Society · 2025Article
- Metabolic engineering approaches for the biosynthesis of antibiotics.Microbial cell factories · 2025Review
- Improving polyketide biosynthesis by rescuing the translation of truncated mRNAs into functional polyketide synthase subunits.Nature communications · 2025Article
- Engineering the TetR-family transcriptional regulator XNR_0706 to enhance heterologous spinosad production inSynthetic and systems biotechnology · 2025Article
- Stepwise increase of fidaxomicin in an engineered heterologous hostSynthetic and systems biotechnology · 2024Article
- Genomic and physiological characterization of Kitasatospora sp. nov., an actinobacterium with potential for biotechnological application isolated from Cerrado soil.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- Discovery, characterization, and engineering of an advantageous Streptomyces host for heterologous expression of natural product biosynthetic gene clusters.Microbial cell factories · 2024Article
- From waste to health-supporting molecules: biosynthesis of natural products from lignin-, plastic- and seaweed-based monomers using metabolically engineered Streptomyces lividans.Microbial cell factories · 2023Article
- Identification and characterization of a strong constitutive promoter stnYp for activating biosynthetic genes and producing natural products in streptomyces.Microbial cell factories · 2023Article
- Cost-effective hybrid long-short read assembly delineates alternative GC-richSynthetic and systems biotechnology · 2023Article
- Optimized De Novo Eriodictyol Biosynthesis inInternational journal of molecular sciences · 2023Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Streptomyces albus J1074 strain is one of the most widely used chassis for the heterologous production of bioactive natural products. The fast growth and an efficient genetic system make this strain an attractive model for expressing cryptic biosynthetic pathways to aid drug discovery.
resultsTo improve its capabilities for the heterologous expression of biosynthetic gene clusters, the complete genomic sequence of S. albus J1074 was obtained. With a size of 6,841,649 bp, coding for 5,832 genes, its genome is the smallest within the genus streptomycetes. Genome analysis revealed a strong tendency to reduce the number of genetic duplicates. The whole transcriptomes were sequenced at different time points to identify the early metabolic switch from the exponential to the stationary phase in S. albus J1074.
conclusionsS. albus J1074 carries the smallest genome among the completely sequenced species of the genus Streptomyces. The detailed genome and transcriptome analysis discloses its capability to serve as a premium host for the heterologous production of natural products. Moreover, the genome revealed 22 additional putative secondary metabolite gene clusters that reinforce the strain's potential for natural product synthesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.